Neutralizing Monoclonal Antibodies against the Gn and the Gc of the Andes Virus Glycoprotein Spike Complex Protect from Virus Challenge in a Preclinical Hamster Model

ABSTRACT Hantaviruses are the etiological agent of hemorrhagic fever with renal syndrome (HFRS) and hantavirus cardiopulmonary syndrome (HCPS). The latter is associated with case fatality rates ranging from 30% to 50%. HCPS cases are rare, with approximately 300 recorded annually in the Americas. Re...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	James Duehr, Meagan McMahon, Brandi Williamson, Fatima Amanat, Alan Durbin, David W. Hawman, Danny Noack, Skyler Uhl, Gene S. Tan, Heinz Feldmann, Florian Krammer
Formato:	article
Lenguaje:	EN
Publicado:	American Society for Microbiology 2020
Materias:	Andes virus hantavirus MAb Sin Nombre virus Microbiology QR1-502
Acceso en línea:	https://doaj.org/article/a07b27d030d04b76a86ce12028632023
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:a07b27d030d04b76a86ce12028632023
record_format	dspace
spelling	oai:doaj.org-article:a07b27d030d04b76a86ce120286320232021-11-15T15:57:02ZNeutralizing Monoclonal Antibodies against the Gn and the Gc of the Andes Virus Glycoprotein Spike Complex Protect from Virus Challenge in a Preclinical Hamster Model10.1128/mBio.00028-202150-7511https://doaj.org/article/a07b27d030d04b76a86ce120286320232020-04-01T00:00:00Zhttps://journals.asm.org/doi/10.1128/mBio.00028-20https://doaj.org/toc/2150-7511ABSTRACT Hantaviruses are the etiological agent of hemorrhagic fever with renal syndrome (HFRS) and hantavirus cardiopulmonary syndrome (HCPS). The latter is associated with case fatality rates ranging from 30% to 50%. HCPS cases are rare, with approximately 300 recorded annually in the Americas. Recently, an HCPS outbreak of unprecedented size has been occurring in and around Epuyén, in the southwestern Argentinian state of Chubut. Since November of 2018, at least 29 cases have been laboratory confirmed, and human-to-human transmission is suspected. Despite posing a significant threat to public health, no treatment or vaccine is available for hantaviral disease. Here, we describe an effort to identify, characterize, and develop neutralizing and protective antibodies against the glycoprotein complex (Gn and Gc) of Andes virus (ANDV), the causative agent of the Epuyén outbreak. Using murine hybridoma technology, we generated 19 distinct monoclonal antibodies (MAbs) against ANDV GnGc. When tested for neutralization against a recombinant vesicular stomatitis virus expressing the Andes glycoprotein (GP) (VSV-ANDV), 12 MAbs showed potent neutralization and 8 showed activity in an antibody-dependent cellular cytotoxicity reporter assay. Escape mutant analysis revealed that neutralizing MAbs targeted both the Gn and the Gc. Four MAbs that bound different epitopes were selected for preclinical studies and were found to be 100% protective against lethality in a Syrian hamster model of ANDV infection. These data suggest the existence of a wide array of neutralizing antibody epitopes on hantavirus GnGc with unique properties and mechanisms of action. IMPORTANCE Infections with New World hantaviruses are associated with high case fatality rates, and no specific vaccine or treatment options exist. Furthermore, the biology of the hantaviral GnGc complex, its antigenicity, and its fusion machinery are poorly understood. Protective monoclonal antibodies against GnGc have the potential to be developed into therapeutics against hantaviral disease and are also great tools to elucidate the biology of the glycoprotein complex.James DuehrMeagan McMahonBrandi WilliamsonFatima AmanatAlan DurbinDavid W. HawmanDanny NoackSkyler UhlGene S. TanHeinz FeldmannFlorian KrammerAmerican Society for MicrobiologyarticleAndes virushantavirusMAbSin Nombre virusMicrobiologyQR1-502ENmBio, Vol 11, Iss 2 (2020)
institution	DOAJ
collection	DOAJ
language	EN
topic	Andes virus hantavirus MAb Sin Nombre virus Microbiology QR1-502
spellingShingle	Andes virus hantavirus MAb Sin Nombre virus Microbiology QR1-502 James Duehr Meagan McMahon Brandi Williamson Fatima Amanat Alan Durbin David W. Hawman Danny Noack Skyler Uhl Gene S. Tan Heinz Feldmann Florian Krammer Neutralizing Monoclonal Antibodies against the Gn and the Gc of the Andes Virus Glycoprotein Spike Complex Protect from Virus Challenge in a Preclinical Hamster Model
description	ABSTRACT Hantaviruses are the etiological agent of hemorrhagic fever with renal syndrome (HFRS) and hantavirus cardiopulmonary syndrome (HCPS). The latter is associated with case fatality rates ranging from 30% to 50%. HCPS cases are rare, with approximately 300 recorded annually in the Americas. Recently, an HCPS outbreak of unprecedented size has been occurring in and around Epuyén, in the southwestern Argentinian state of Chubut. Since November of 2018, at least 29 cases have been laboratory confirmed, and human-to-human transmission is suspected. Despite posing a significant threat to public health, no treatment or vaccine is available for hantaviral disease. Here, we describe an effort to identify, characterize, and develop neutralizing and protective antibodies against the glycoprotein complex (Gn and Gc) of Andes virus (ANDV), the causative agent of the Epuyén outbreak. Using murine hybridoma technology, we generated 19 distinct monoclonal antibodies (MAbs) against ANDV GnGc. When tested for neutralization against a recombinant vesicular stomatitis virus expressing the Andes glycoprotein (GP) (VSV-ANDV), 12 MAbs showed potent neutralization and 8 showed activity in an antibody-dependent cellular cytotoxicity reporter assay. Escape mutant analysis revealed that neutralizing MAbs targeted both the Gn and the Gc. Four MAbs that bound different epitopes were selected for preclinical studies and were found to be 100% protective against lethality in a Syrian hamster model of ANDV infection. These data suggest the existence of a wide array of neutralizing antibody epitopes on hantavirus GnGc with unique properties and mechanisms of action. IMPORTANCE Infections with New World hantaviruses are associated with high case fatality rates, and no specific vaccine or treatment options exist. Furthermore, the biology of the hantaviral GnGc complex, its antigenicity, and its fusion machinery are poorly understood. Protective monoclonal antibodies against GnGc have the potential to be developed into therapeutics against hantaviral disease and are also great tools to elucidate the biology of the glycoprotein complex.
format	article
author	James Duehr Meagan McMahon Brandi Williamson Fatima Amanat Alan Durbin David W. Hawman Danny Noack Skyler Uhl Gene S. Tan Heinz Feldmann Florian Krammer
author_facet	James Duehr Meagan McMahon Brandi Williamson Fatima Amanat Alan Durbin David W. Hawman Danny Noack Skyler Uhl Gene S. Tan Heinz Feldmann Florian Krammer
author_sort	James Duehr
title	Neutralizing Monoclonal Antibodies against the Gn and the Gc of the Andes Virus Glycoprotein Spike Complex Protect from Virus Challenge in a Preclinical Hamster Model
title_short	Neutralizing Monoclonal Antibodies against the Gn and the Gc of the Andes Virus Glycoprotein Spike Complex Protect from Virus Challenge in a Preclinical Hamster Model
title_full	Neutralizing Monoclonal Antibodies against the Gn and the Gc of the Andes Virus Glycoprotein Spike Complex Protect from Virus Challenge in a Preclinical Hamster Model
title_fullStr	Neutralizing Monoclonal Antibodies against the Gn and the Gc of the Andes Virus Glycoprotein Spike Complex Protect from Virus Challenge in a Preclinical Hamster Model
title_full_unstemmed	Neutralizing Monoclonal Antibodies against the Gn and the Gc of the Andes Virus Glycoprotein Spike Complex Protect from Virus Challenge in a Preclinical Hamster Model
title_sort	neutralizing monoclonal antibodies against the gn and the gc of the andes virus glycoprotein spike complex protect from virus challenge in a preclinical hamster model
publisher	American Society for Microbiology
publishDate	2020
url	https://doaj.org/article/a07b27d030d04b76a86ce12028632023
work_keys_str_mv	AT jamesduehr neutralizingmonoclonalantibodiesagainstthegnandthegcoftheandesvirusglycoproteinspikecomplexprotectfromviruschallengeinapreclinicalhamstermodel AT meaganmcmahon neutralizingmonoclonalantibodiesagainstthegnandthegcoftheandesvirusglycoproteinspikecomplexprotectfromviruschallengeinapreclinicalhamstermodel AT brandiwilliamson neutralizingmonoclonalantibodiesagainstthegnandthegcoftheandesvirusglycoproteinspikecomplexprotectfromviruschallengeinapreclinicalhamstermodel AT fatimaamanat neutralizingmonoclonalantibodiesagainstthegnandthegcoftheandesvirusglycoproteinspikecomplexprotectfromviruschallengeinapreclinicalhamstermodel AT alandurbin neutralizingmonoclonalantibodiesagainstthegnandthegcoftheandesvirusglycoproteinspikecomplexprotectfromviruschallengeinapreclinicalhamstermodel AT davidwhawman neutralizingmonoclonalantibodiesagainstthegnandthegcoftheandesvirusglycoproteinspikecomplexprotectfromviruschallengeinapreclinicalhamstermodel AT dannynoack neutralizingmonoclonalantibodiesagainstthegnandthegcoftheandesvirusglycoproteinspikecomplexprotectfromviruschallengeinapreclinicalhamstermodel AT skyleruhl neutralizingmonoclonalantibodiesagainstthegnandthegcoftheandesvirusglycoproteinspikecomplexprotectfromviruschallengeinapreclinicalhamstermodel AT genestan neutralizingmonoclonalantibodiesagainstthegnandthegcoftheandesvirusglycoproteinspikecomplexprotectfromviruschallengeinapreclinicalhamstermodel AT heinzfeldmann neutralizingmonoclonalantibodiesagainstthegnandthegcoftheandesvirusglycoproteinspikecomplexprotectfromviruschallengeinapreclinicalhamstermodel AT floriankrammer neutralizingmonoclonalantibodiesagainstthegnandthegcoftheandesvirusglycoproteinspikecomplexprotectfromviruschallengeinapreclinicalhamstermodel
_version_	1718427042522857472

Neutralizing Monoclonal Antibodies against the Gn and the Gc of the Andes Virus Glycoprotein Spike Complex Protect from Virus Challenge in a Preclinical Hamster Model

Ejemplares similares